Companies / Belgium
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
UCB Posts Robust Financial Results
August 2006 | Company Finance AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Matching compatriot firm Solvay, Belgian drugmaker UCB has released strong financial results for the first half of 2006 in which revenues increased by 12% to EUR1.3bn (US$1.7bn). Net profit from continuing operations rose by 44% to EUR237mn (US$303mn), including a net capital gain of EUR57mn (US$73mn) on the sale of non-core businesses and brands, and after restructuring expenses.